Human adenovirus 2 (Ad2) encodes an E3 11,600 MW protein named the """"""""Adenovirus Death Protein"""""""" (ADP). ADP is a nuclear (NM) glycoprotein synthesized in large amounts at late stages of infection. ADP colocalizes with Ad2 E1B-19K, a homolog of Bcl-2 which maintains cell viability. ADP may supersede the ability of E1B-19K to inhibit cell death; therefore, cells lyse and release virus. Structure-function analyses have identified domains required for ADP to promote cell death and be sorted from the ER to the Golgi and the NM where ADP functions to promote cell death. We propose to determine if ADP alone promotes cell death, it abrogates the ability of E1B-19K to inhibit cytolysis by TNF or anti-Fas, it affects the functions of the ICE family (which induces death), and it kills cells by apoptosis. The 'death' domains of ADP will be mutated to gain insight into how they function. Protein-protein interactions will be examined by coimmunoprecipitation using antisera to ADP and epitope tagged ADP, affinity binding to a GST- ADP fusion protein, and the yeast two-hybrid system. Cellular proteins that bind ADP will be cloned and characterized. We will focus on whether ADP binds to E1B-19K, cellular proteins that bind to E1B-19K, and to members of the Bcl-2 family. We will determine whether ADP localizes to the inner or outer NM, then use existing mutants to identify in transient transfections the domains in ADP necessary for transport of ADP from the trans-Golgi network to the NM, and for the interaction of ADP with E1B-19K. A CD8-ADP reporter will be used to identify sequences in ADP sufficient for targeting to the NM. ADP will be monitored by confocal immunofluorescence and by equilibrium density centrifugation of membrane fractions. ADP is a novel protein, and it represents a new concept in viral pathogenesis. ADP should be a powerful tool to understand apoptosis and the function of the E1B-19K oncoprotein, and perhaps members of the Bcl-2 family. ADP might also be used as a 'suicide' gene to kill cancer cells.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA071704-03
Application #
2712812
Study Section
Experimental Virology Study Section (EVR)
Program Officer
Wong, May
Project Start
1996-08-01
Project End
2001-05-31
Budget Start
1998-06-01
Budget End
1999-05-31
Support Year
3
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Saint Louis University
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
City
Saint Louis
State
MO
Country
United States
Zip Code
63103
Kuppuswamy, M; Spencer, J F; Doronin, K et al. (2005) Oncolytic adenovirus that overproduces ADP and replicates selectively in tumors due to hTERT promoter-regulated E4 gene expression. Gene Ther 12:1608-17
Toth, Karoly; Spencer, Jacqueline F; Tollefson, Ann E et al. (2005) Cotton rat tumor model for the evaluation of oncolytic adenoviruses. Hum Gene Ther 16:139-46
Toth, Karoly; Djeha, Hakim; Ying, Baoling et al. (2004) An oncolytic adenovirus vector combining enhanced cell-to-cell spreading, mediated by the ADP cytolytic protein, with selective replication in cancer cells with deregulated wnt signaling. Cancer Res 64:3638-44
Ying, Baoling; Wold, William S M (2003) Adenovirus ADP protein (E3-11.6K), which is required for efficient cell lysis and virus release, interacts with human MAD2B. Virology 313:224-34
Tollefson, Ann E; Scaria, Abraham; Ying, Baoling et al. (2003) Mutations within the ADP (E3-11.6K) protein alter processing and localization of ADP and the kinetics of cell lysis of adenovirus-infected cells. J Virol 77:7764-78
Doronin, Konstantin; Toth, Karoly; Kuppuswamy, Mohan et al. (2003) Overexpression of the ADP (E3-11.6K) protein increases cell lysis and spread of adenovirus. Virology 305:378-87
Toth, Karoly; Tarakanova, Vera; Doronin, Konstantin et al. (2003) Radiation increases the activity of oncolytic adenovirus cancer gene therapy vectors that overexpress the ADP (E3-11.6K) protein. Cancer Gene Ther 10:193-200
Habib, Nagy A; Mitry, Ragai; Seth, Prem et al. (2002) Adenovirus replication-competent vectors (KD1, KD3) complement the cytotoxicity and transgene expression from replication-defective vectors (Ad-GFP, Ad-Luc). Cancer Gene Ther 9:651-4
Doronin, K; Kuppuswamy, M; Toth, K et al. (2001) Tissue-specific, tumor-selective, replication-competent adenovirus vector for cancer gene therapy. J Virol 75:3314-24
Doronin, K; Toth, K; Kuppuswamy, M et al. (2000) Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein. J Virol 74:6147-55

Showing the most recent 10 out of 12 publications